| Drug Name |
Retapamulin |
| Drug ID |
BADD_D01928 |
| Description |
Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007. |
| Indications and Usage |
For use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. |
| Marketing Status |
approved |
| ATC Code |
D06AX13 |
| DrugBank ID |
DB01256
|
| KEGG ID |
D05720
|
| MeSH ID |
C508887
|
| PubChem ID |
6918462
|
| TTD Drug ID |
D03UQM
|
| NDC Product Code |
16110-518 |
| UNII |
4MG6O8991R
|
| Synonyms |
retapamulin | acetic acid, 2-(((3-exo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester | SB 275833 | SB275833 | SB-275833 | Altabax | Altargo |
